Tidblad A, Gustafsson J, Marcus C, et al. - In short children with growth hormone (GH) peak levels in the low to normal range, researchers examined the metabolic impacts of different doses of GH in this double-blinded randomized clinical trial. They randomized 35 prepubertal short children (<−2.5 SDS), aged 7 to 10 years, with peak GH levels between 7 and 14 μg/L during an arginine-insulin tolerance test, to three different doses (11/33/100 μg/kg/day) of GH treatment for 2 years. In both HOMA indices and frequently sampled intravenous glucose tolerance test examinations, GH treatment resulted in a dose-dependent lowering of insulin sensitivity, as indicated by higher fasting insulin levels and signs of insulin resistance. The high-dose group (HD) had higher fasting insulin at 24 months vs the standard-dose (SD) and low-dose (LD) groups. Not many other metabolic differences were seen at 24 months, but a lower insulin sensitivity index was seen at 12 months for both SD and HD vs the LD group.